Planet 13: High-Risk Call Option on Cannabis Rescheduling With a Ticking Liquidity Clock
This report provides a detailed investment analysis of Planet 13 Holdings Inc. (PLTH.CN/PLNH), a vertically-integrated multi-state cannabis operator (MSO) in the United States. The company's business model is structured around a "barbell" strategy. This consists of its "Brand Engine," the iconic, 112,000-square-foot SuperStore entertainment complex in Las Vegas, Nevada, and its "Growth Engine," a recently acquired and expanding network of over 30 "neighborhood" dispensaries across Florida. This Florida footprint was established through the May 2024 acquisition of VidaCann.
Recent strategic actions, culminating in the November 2025 announcement to divest all California assets, signal a significant defensive pivot. The company is now focused almost exclusively on this two-state (Nevada/Florida) model.
The resulting investment thesis is a high-stakes, binary proposition. The company is currently unprofitable on an Adjusted EBITDA basis and is depleting a dwindling cash balance. Its viability appears to be a race against time: can the company achieve operational cash flow before its liquidity is exhausted, or will it be saved by the deus ex machina of federal cannabis rescheduling? Rescheduling would eliminate the crippling 26 U.S.C. § 280E (280E) tax burden, which is the primary driver of its net losses.
The recent and indefinite postponement of Drug Enforcement Administration (DEA) rescheduling hearings has significantly extended the company's period of financial distress. This delay makes its near-term liquidity runway and the high potential for shareholder dilution the single most important factors for investors.
Planet 13's core business model is that of a vertically-integrated cannabis company. It participates in the entire value chain, from cultivation and processing to retail sales and branded product manufacturing. This vertical integration is designed to capture margin at each step and build a portfolio of recognizable in-house brands, which include Medizin (flower, vapes), TRENDI (vapes, concentrates), HaHa (gummies, beverages), and Dreamland (chocolates).
On November 3, 2025, Planet 13 announced a major strategic rationalization of its footprint. The company divested its non-core Orange County, California retail store and simultaneously announced the closure of its cultivation facility in Coalinga, California.
Management stated these California operations were "cash-flow negative" and no longer aligned with the company's long-term objectives. The stated strategy is now to "continue to invest in expanding its presence in Nevada and Florida". This move, presented as "disciplined capital allocation", appears to be more of a defensive necessity. The company’s Q1 and Q2 2025 financial reports revealed negative Adjusted EBITDA and a rapidly declining cash balance, which stood at only $15.9 million as of June 30, 2025. This exit was likely not a strategic choice, but a non-negotiable requirement to stanch cash burn. Management's admission that the proceeds from the sale were "not material" reinforces the conclusion that the primary goal was to stop the operational bleeding.
The company's identity and historically its primary cash-flow engine is the Las Vegas SuperStore. Billed as the "nation's largest dispensary", it functions as a high-traffic tourist destination that serves as a massive branding platform.
To further monetize this unique asset, the company recently debuted "DAZED!", its first cannabis consumption lounge, located inside the SuperStore. This addition is a critical attempt to increase the average ticket size from a tourist base that management admits is shrinking (citing a "decline in tourism") and spending less (citing a "drop in average spending"). The SuperStore's competitive moat is proving vulnerable to market-wide price compression and a weaker consumer, forcing management to find new ways to monetize its existing square footage.
Planet 13's entire growth strategy is now centered on the Florida market. This was enabled by the closing of the VidaCann acquisition on May 10, 2024.
Acquisition Details: The transaction was valued at approximately $63.4 million, comprising 81.9 million shares, $4 million in cash, and $5 million in promissory notes. This valuation was a fraction of the $120 million Cresco Labs had offered for the same asset in 2019, reflecting the deterioration in the market.
Acquired Assets: The acquisition provided Planet 13 with an immediate footprint of 26 existing medical dispensaries. More importantly, it included a "fully-operational, greenhouse cultivation facility" with the state-of-the-art processing capacity to support "more than double" the combined dispensary network.
The Rollout: Planet 13 is leveraging this infrastructure to rapidly open new "neighborhood" dispensaries, such as the new locations in DeLand (October 13, 2025) and Pace (October 20, 2025). This has brought its total Florida footprint to over 30 stores.
This creates a "Barbell Strategy" of two fundamentally different business models. The Las Vegas SuperStore is a high-margin, experiential destination, while the Florida stores are high-volume, "neighborhood" medical dispensaries. The skills and brand identity are not easily transferable. This suggests the company could not afford its preferred "SuperStore" strategy in Florida and was instead forced to buy a generic, sub-scale asset (VidaCann) to gain market access.
The company operates a single dispensary in Waukegan, Illinois, which serves the Chicago metropolitan area. While management has cited Illinois as a growth market, it remains a distant third priority behind the core Nevada and Florida assets.
For the full year ended December 31, 2024, Planet 13 reported total revenue of $116.4 million. This represented an 18.2% increase from 2023, with the growth explicitly "driven by the addition of Florida". Gross profit was $56.1 million, a 48.2% margin, which was a significant improvement from 2023.
While the company posted a large net loss of $47.8 million , a figure highly distorted by the 280E tax burden, it crucially reported positive Adjusted EBITDA of $3.5 million for the full year. This establishes a 2024 baseline of a barely profitable operation before the sharp deterioration seen in 2025.
The first half of 2025 revealed a dramatic collapse in profitability.
Q1 2025: Revenue was $28.0 million. The company reported a net loss of (2.5) million.
Q2 2025: Revenue declined sequentially to $26.9 million. The net loss ballooned to (2.4) million.
Management attributed this poor performance to "price compression and a weaker consumer environment in Nevada and increased competition in Florida".
The 2024-2025 data shows a strong correlation between the Florida acquisition and the collapse in profitability. The company went from +$3.5 million in Adjusted EBITDA (FY 2024) to a negative run-rate of approximately $(4.9) million in Adjusted EBITDA (H1 2025). This strongly implies the VidaCann acquisition, rather than being a new growth engine, is a significant cash-burning anchor, likely due to "targeted discounting" in Florida's "fierce" medical market.
The following table visually demonstrates the sharp 2025 deterioration in profitability and the collapse of Adjusted EBITDA, the most critical metric for assessing operational health and cash-burn.
Table 3.1: Key Historical Financials (USD, in Millions) (Data Provenance:,,)
The company's balance sheet reflects a precarious financial position.
Cash: $15.9 million. This is down from $23.4 million at year-end 2024.
Total Debt: $58.7 million.
This creates a "liquidity death clock" scenario. The company burned $7.5 million in cash during the first six months of 2025 ($23.4M minus $15.9M). This implies an average quarterly cash burn of $3.75 million. With only $15.9 million in cash remaining, the company has approximately 4.2 quarters of liquidity ($15.9M / $3.75M). This projects a potential insolvency date in Q3 2026. This is not a long-term risk; it is an immediate, existential threat. The upcoming Q3 2025 earnings (scheduled for November 12, 2025) will be critical to see if this burn rate has been arrested.
Share Price: C$0.275. The USD equivalent (PLNH) is approximately $0.20.
Shares Outstanding: 325.4 million.
Market Cap: Approximately C$89.5 million (USD equivalent ~ $65 million).
Enterprise Value (EV):
Market Cap: ~$65M
Plus: Total Debt: $58.7M
Less: Cash: $15.9M
EV = ~$107.8M
LTM Revenue (as of Q2 2025): $117.4M (Q2'25 $26.9M + Q1'25 $28.0M + Q4'24 $30.3M + Q3'24 $32.2M).
LTM Adj. EBITDA (as of Q2 2025): $(3.6)M (Q2'25 $(2.4)M + Q1'25 $(2.5)M + Q4'24 $0.0M + Q3'24 $1.3M).
The company's current valuation cannot be based on traditional earnings multiples, as it has no earnings.
Table 3.2: Current Valuation Multiples (Data Provenance: Calculations based on )
With negative EBITDA and a liquidity runway of less than 1.5 years, the $108M Enterprise Value is not a valuation of the current business. It is the market's price for the option that the company's assets (its licenses, the SuperStore, and 30+ Florida stores) will be "unlocked" by 280E tax relief before the company goes bankrupt or dilutes shareholders to zero.
Cannabis remains a Schedule I controlled substance under federal law, making it illegal. The primary consequence of this is the 280E tax burden. Under IRS Code 26 U.S.C. § 280E, businesses trafficking in Schedule I or II substances are prohibited from deducting ordinary and necessary business expenses, such as rent, payroll, and marketing.
Planet 13 is therefore forced to pay federal income taxes on its gross profit, not its net income. This creates an "exorbitant federal tax rate" and "significantly lower[s]... cash flow", representing a "significant financial burden". This tax burden is the direct cause of the $47.8 million net loss reported in 2024, a year in which the company was actually profitable on an Adjusted EBITDA basis.
The most significant potential catalyst for the entire industry is the proposed rescheduling of cannabis. In May 2024, the DEA proposed moving cannabis from Schedule I to Schedule III, a move that would formally acknowledge its medical use.
This is the "golden ticket" for MSOs. The 280E tax provision does not apply to Schedule III substances. If this rule is finalized, 280E would be eliminated for Planet 13, "fundamentally chang[ing] the tax structure of the industry" and immediately improving net income and cash flow.
This is the most critical and immediate risk. The DEA administrative hearings, which were scheduled to begin on January 21, 2025, were indefinitely postponed by the Administrative Law Judge (ALJ). The ALJ "suspend[ed] proceedings" to allow for an "interlocutory appeal" to be resolved.
This is not a minor bureaucratic delay; it procedurally kills the catalyst for the foreseeable future. This delay directly causes the liquidity risk (Risk 3) to become existential. Planet 13 must continue to pay the punitive 280E tax and bleed cash for an unknown number of additional quarters, a luxury that its 4-quarter liquidity runway does not afford.
As detailed in Section 3, the company's $15.9 million cash balance and negative Adjusted EBITDA create a high probability of a highly dilutive capital raise within the next 12 months. This risk is compounded by the 280E delay. The company is now in a race: can it fix its operations to become cash-flow positive before the 280E delay forces a "rescue financing" at a deep discount to the current stock price?
Nevada: The flagship "cash cow" asset is under attack. Management has repeatedly cited "industry-wide price compression", a "weaker consumer", and a "decline in tourism". The company is "lean[ing] in on price" to maintain market share, which is destroying its gross margins.
Florida: The new "growth engine" is already sputtering. Management admitted that Q2 2025 results were negatively impacted by "increased competition in Florida". The company entered this market after the 2024 recreational ballot measure failed. This means Planet 13 is now a sub-scale operator (with ~30 stores) in a "fierce", over-saturated medical market that already has 736 dispensaries. This represents a significant strategy-market mismatch.
This analysis is a bottom-up fundamental model. The objective is to derive a 2030 share price based on explicit, justifiable assumptions, not by extrapolating from the current distressed price. All price targets are outputs of the model.
Core Model Assumptions (Provenance):
Current Shares: 325.4 million.
Valuation: A terminal (2030) EV/EBITDA multiple. A derisked, post-280E MSO could theoretically trade between 11.2x and 16.75x. A conservative range of 8.0x (Low) to 14.0x (High) is used.
Nevada (Base): The SuperStore and wholesale operations are treated as a mature asset. The Base Case models $75 million in revenue at a 15% Adjusted EBITDA margin, reflecting "price compression".
Florida (Base): A slow maturation of stores is assumed in the competitive medical market. The Base Case models a "run-rate" (mature store) revenue of $3.0 million/year per store.
Illinois (Base): The single Waukegan store is modeled as a $15 million/year revenue asset at a 15% margin.
Corporate Overhead: A $15 million annual G&A drag is assumed.
Narrative: The 280E relief is delayed by legal appeals and is not implemented until H2 2027 (effective Jan 1, 2028). The company's cash-burn forces a $20 million dilutive equity raise in 2026 to survive. The Florida market remains medical-only, and the store ramp-up is slow.
Key Fundamental Inputs:
280E Relief: Effective Jan 1, 2028.
Financing (2026): $20 million raise at $0.15/share (US) (a 25% discount to current price).
New Shares Issued: 133.3 million shares.
Pro-Forma Share Count: 325.4M + 133.3M = 458.7 million shares.
Nevada: Revenue: $75M/year. Adj. EBITDA Margin: 15%. (Adj. EBITDA: $11.25M).
Florida: Slow organic growth to 45 stores by 2030. Stores mature at $3.0M/year.
Florida Revenue (2030): 45 stores $3.0M = $135M.
Florida Adj. EBITDA (2030): $135M 10% margin = $13.5M.
Illinois: Revenue: $15M/year. Adj. EBITDA: $15M 15% margin = $2.25M.
Corporate: Adj. EBITDA: $(15.0)M.
2030 Calculation:
Total Revenue: $75M + $135M + $15M = $225M.
Total Adj. EBITDA: $11.25M (NV) + $13.5M (FL) + $2.25M (IL) - $15.0M (Corp) = $12.0M.
Terminal Multiple: 10.0x (A "survived-but-damaged" MSO multiple).
Enterprise Value (2030): $12.0M 10.0x = $120M.
Net Debt (2030): Assumed $40M (debt remains).
Equity Value (2030): $120M (EV) - $40M (Net Debt) = $80M.
Price Per Share (2030): $80M / 458.7M shares = $0.17
Narrative: The 280E procedural delay is resolved quickly, and rescheduling is finalized by mid-2026 (effective Jan 1, 2027). The immediate tax savings and potential refunds prevent any significant dilution. Florida passes adult-use recreational cannabis in 2028, and store revenues explode.
Key Fundamental Inputs:
280E Relief: Effective Jan 1, 2027.
Financing (2026): None. Share Count: 330 million (minor options/RSU vesting).
Nevada: Revenue grows 2% a year to $85M (brand strengthened by post-280E marketing). Adj. EBITDA Margin: 25%. (Adj. EBITDA: $21.25M).
Florida: Aggressive growth to 60 stores (approaching cultivation capacity). Stores mature at $4.5M/year (reflecting a robust adult-use market).
Florida Revenue (2030): 60 stores $4.5M = $270M.
Florida Adj. EBITDA (2030): $270M 20% margin = $54.0M.
Illinois: Grows to $25M/year. Adj. EBITDA: $25M 20% margin = $5.0M.
Corporate: Adj. EBITDA: $(18.0)M (higher growth costs).
2030 Calculation:
Total Revenue: $85M + $270M + $25M = $380M.
Total Adj. EBITDA: $21.25M (NV) + $54.0M (FL) + $5.0M (IL) - $18.0M (Corp) = $62.25M.
Terminal Multiple: 14.0x (A derisked, high-growth MSO multiple).
Enterprise Value (2030): $62.25M 14.0x = $871.5M.
Net Debt (2030): Assumed $(50)M (FCF generation post-280E pays off all debt and builds a cash balance).
Equity Value (2030): $871.5M (EV) + $50M (Net Cash) = $921.5M.
Price Per Share (2030): $921.5M / 330M shares = $2.79
Narrative: 280E relief is blocked in court past 2028. The company's cash is fully depleted by mid-2026. A massive $30 million "rescue financing" is required at a deep discount, leading to catastrophic dilution. The Florida build-out stalls, and the Nevada price war turns the SuperStore into a break-even asset.
Key Fundamental Inputs:
280E Relief: Delayed past 2029.
Financing (2026): $30 million raise at $0.10/share (US) (a 50% discount).
New Shares Issued: 300 million shares.
Pro-Forma Share Count: 325.4M + 300M = 625.4 million shares.
Nevada: Revenue stagnates at $70M. Adj. EBITDA Margin: 5% (due to "leaning in on price"). (Adj. EBITDA: $3.5M).
Florida: Store count stalls at 35 (lack of capital). Stores mature at only $2.5M/year (stuck in hyper-competitive medical market).
Florida Revenue (2030): 35 stores $2.5M = $87.5M.
Florida Adj. EBITDA (2030): $87.5M 5% margin = $4.38M.
Illinois: Stagnant at $10M. Adj. EBITDA: $10M 5% margin = $0.5M.
Corporate: Adj. EBITDA: $(10.0)M (costs cut to the bone).
2030 Calculation:
Total Revenue: $70M + $87.5M + $10M = $167.5M.
Total Adj. EBITDA: $3.5M (NV) + $4.38M (FL) + $0.5M (IL) - (1.62)M*.
Enterprise Value (2030): Not meaningful. The company is still unprofitable.
Equity Value (2030): $0. The equity is worthless as the company is insolvent or has been acquired for its debt.
Price Per Share (2030): $0.00
The following table synthesizes the models, showing the extreme binary nature of the investment and the high probability of dilution.
Table 5.1: 5-Year Price Target Summary (USD) (Data Provenance: Output from the three scenarios modeled above)
The probability-weighted target of $0.77 (USD) suggests the market is currently undervaluing the optionality of the High Case. However, this average outcome is highly misleading. The 30% chance of a total loss (Low Case) and 45% chance of a negative return (Base Case) mean there is a 75% probability of losing money or breaking even on this investment over the 5-year period. The thesis is entirely dependent on the low-probability "High Case" occurring.
BOLD SUMMARY: High-Stakes Binary
Management Alignment: (Score: 5/10)
Narrative: High insider ownership by Co-CEO Bob Groesbeck (11.39% of the company) is a strong positive alignment, as the founders (Groesbeck and Scheffler) remain at the helm. However, this is significantly offset by questionable compensation practices. In 2024, a year of unprofitability, the Co-CEOs each received a $312,500 cash bonus on top of a $500,000 salary. Rewarding management with cash bonuses while the company is unprofitable and burning cash demonstrates poor alignment with shareholder interests.
Revenue Quality: (Score: 3/10)
Narrative: Revenue quality is extremely low. It is volatile, as demonstrated by the 13.6% year-over-year decline in Q2 2025. Revenue is being "bought" with heavy "price compression" and "targeted discounting". This is unprofitable revenue, as evidenced by the negative Adjusted EBITDA.
Market Position: (Score: 5/10)
Narrative: This is a "Tale of Two Cities." In Nevada, the company possesses an iconic, 10/10 market-leading "SuperStore" asset. In Florida, it is a sub-scale, 2/10 player, with only ~4% of the state's dispensaries (30 of 736) and no meaningful brand differentiation. The recent California exit was a concession of defeat in that market.
Growth Outlook: (Score: 7/10)
Narrative: The potential for growth is high. The Florida cultivation infrastructure can support a doubling of the current store count. If 280E is resolved and Florida passes adult-use recreational sales, the growth would be explosive. This score is high based on this potential, but the execution risk is severe.
Financial Health: (Score: 2/10)
Narrative: This is the company's single greatest weakness. With only $15.9 million in cash, $58.7 million in debt, and a quarterly cash burn of ~$3.75 million, the company is on a 12-15 month "death clock". This is a distressed balance sheet, and market concerns over dilution are high.
Business Viability: (Score: 3/10)
Narrative: The current business is not viable. It is operationally unprofitable (negative Adjusted EBITDA) and structurally unprofitable (due to 280E). Its viability is 100% dependent on an external event (280E relief) occurring before an internal event (insolvency).
Capital Allocation: (Score: 4/10)
Narrative: The November 2025 exit from California is a good, disciplined decision. However, this positive move was forced by the seemingly disastrous 2024 VidaCann acquisition, which appears to be the source of the negative EBITDA. The company acquired a cash-burning asset at the worst possible time and is now "streamlining" to pay for it.
Analyst Sentiment: (Score: 5/10)
Narrative: Analyst consensus is a "low confidence" shrug. The average 1-year price target is $0.59 (USD), implying 204% upside. However, this comes with a "Low Agreement" warning, indicating analysts are deeply divided, which reduces the target's credibility. The consensus 2026 EBITDA forecast is a wafer-thin $3 million.
Profitability: (Score: 1/10)
Narrative: The company is unprofitable on every important metric. This includes a Net Loss ((2.4)M in Q2). The 48.2% gross margin from 2024 is a "melting ice cube" that is gone before it hits the bottom line.
Track Record: (Score: 3/10)
Narrative: Management has a track record of building one successful asset (the SuperStore). They have a dismal track record of creating shareholder value, with the 5-year stock performance at -94%. Recent insider activity is also negative: the VP of Operations, Chris Wren, has been consistently selling shares in September, October, and November 2025. This is a strong negative signal from a key operational leader.
Overall Blended Score: 4.0/10
BOLD SUMMARY: Show-Me Story
Investment Thesis: An investment in Planet 13 (PLTH.CN) is a "call option" on federal cannabis rescheduling, offering an extremely high-risk, high-reward, binary outcome. The company is currently operationally and structurally unprofitable.
The Core Conflict: The company is in a race against time. Its liquidity clock is ticking down, with an estimated 12-15 months of cash remaining. Its survival depends on either (A) a rapid, unforeseen operational turnaround to positive Adjusted EBITDA, or (B) the timely arrival of the 280E tax relief catalyst.
The Problem: That catalyst is now indefinitely delayed, while the company's "growth engine" in Florida appears to be a major source of its cash burn.
Key Catalysts:
A favorable, fast resolution to the DEA rescheduling appeal, unlocking 280E tax relief in 2026.
The Q3 2025 earnings call (November 12) showing a material reduction in cash burn and a return to positive Adjusted EBITDA.
Key Risks:
The 280E delay extends into 2027, forcing a highly dilutive "rescue financing" in 2026 (the "Low Case" scenario).
Continued price compression in Nevada and competition in Florida keeps Adjusted EBITDA negative, accelerating the liquidity crisis.
Continued insider selling from operational management signals a lack of internal confidence.
Final Outlook: The 5-year scenario analysis shows a 75% probability of a negative or zero-return outcome. The investment's potential relies entirely on a low-probability, high-impact "High Case" scenario. The company is fundamentally distressed, and its fate rests in the hands of regulators, not its own management.
BOLD SUMMARY: Awaiting Relief
As of November 5, 2025, PLTH.CN is trading at C$0.275. The stock is in a severe, multi-year downtrend, down 94% from its 5-year high. The US symbol (PLNH) is trading at approximately $0.20, which is significantly below its 200-day moving average of $0.2270, confirming the entrenched bearish trend. Technical indicators are broadly signaling a "Strong Sell". The positive strategic news of the California exit on November 3 was met with a market shrug, while persistent insider selling adds to the negative sentiment. The short-term outlook is negative, with the stock likely to test its all-time lows pending the critical Q3 2025 earnings call on November 12.
BOLD SUMMARY: Technically Weak
View Planet 13 Holdings Inc. (PLTH.CN) stock page
Loading the interactive version of this report…